elymusConnect

Pipeline

Focused first
Scalable by design

Elymus is prioritizing Duchenne muscular dystrophy while building a platform with potential relevance across membrane-instability disorders.

Lead program

Duchenne muscular dystrophy

Preclinical-stage membrane stabilization program

DiscoveryLead optimizationIND-enablingPhase 1
Current focus
ModalityBottlebrush macromoleculeTargetSarcolemma stabilizationStagePreclinical

DMD background

Dystrophin is the molecular shock absorber for normal muscle cell membranes

Duchenne muscular dystrophy is caused by mutations in a gene that results in absent or severely reduced dystrophin. Dystrophin helps connect the muscle cell cytoskeleton to the membrane associated protein complex, supporting the sarcolemma during repeated contraction. Without this support, the membrane becomes vulnerable to disruption and excessive calcium entry. Repeated injury contributes to inflammation, loss of functional muscle tissue, progressive weakness, and loss of mobility.

Elymus is pursuing a physical membrane stabilization approach intended to address this downstream feature of DMD biology, which is mutation agnostic.

Dystrophin mechanical link between the extracellular matrix, muscle-cell membrane, and actin cytoskeleton
Dystrophin provides a mechanical link between the extracellular matrix, muscle-cell membrane, and actin cytoskeleton.
Illustrative overview of DMD progression from early signs to assisted mobility
Illustrative overview of DMD progression; progression varies by individual.

Platform horizon

Membrane instability extends beyond DMD

DMDCore focusOther Muscular DystrophiesFuture researchUndisclosedFuture research

Future indications are exploratory and do not represent active development programs.

Interested in the Elymus platform?

Partner with us